Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : The Microcap Kitchen: Stocks 5¢ to $5 -- Ignore unavailable to you. Want to Upgrade?

To: GARY P GROBBEL who wrote (15612)	12/4/2003 11:21:23 AM
From: GARY P GROBBEL	Respond to of 120415

CVSN 1.26 up .09 heavy vol 170,000...has started to trade heavily last few days...check historical prices...move began around 1.05 4 days back or so: ChromaVision Announces New Image Capture and Transmission Technology Wednesday October 29, 7:32 am ET Image Extractor Allows Electronic Distribution of Automated Image Analysis Information SAN JUAN CAPISTRANO, Calif., Oct. 29 /PRNewswire-FirstCall/ -- ChromaVision Medical Systems, Inc. (Nasdaq: CVSN - News), the leading provider of automated cell-imaging systems and manufacturer of the ACIS® digital microscope system, today announced that it has developed and is implementing a new approach for the distribution of images captured using the ChromaVision ACIS® device. This new capability was initially developed for the Johns Hopkins Kimmel Cancer Center to allow the Center to extract and send images from their ACIS to external databases or to their website for review by third parties or for archiving purposes. The image extraction technology, which is also available for use with Tissue Micro Array applications or for generic histological reconstruction, provides added flexibility for ChromaVision customers and has a number of additional commercial applications involving image transfer and storage. ADVERTISEMENT "Through its user interface, the image extractor provides our customers with a unique way to view, save and share captured images while also controlling a 'quality factor' that targets the desired level of image compression," said Jose Torre-Bueno, Ph.D., ChromaVision's Chief Technology Officer. Torre-Bueno added, "These capabilities are unrivaled in image analysis and give users the flexibility they require for distributed image review and analysis. We believe that this application will have broad appeal to research and clinical applications and is available for current and prospective customers today as an optional configuration to their system." Karen Garza, ChromaVision Vice President of Marketing and Business Development, remarked, "We are pleased to have identified Johns Hopkins' Kimmel Cancer Center as a beta site for the development of ChromaVision's image capture application. Their leadership role in healthcare research and, in particular, the fight against prostate cancer makes them an ideal development partner for this technology." The ability to extract ACIS® images allows the researcher to archive, import or view information via their own database. This feature allows the diagnostic interpretation of each image from multiple locations at different times, facilitates quality control of ACIS® scoring, and can improve the efficiency of research, where the ultimate objective is faster discovery and time to market for important new medical therapies. About ChromaVision Medical Systems, Inc. ChromaVision Medical Systems, Inc., based in San Juan Capistrano, California, develops innovative medical systems to improve anatomic pathology diagnostics through accuracy, standardization and quantitation. ChromaVision's ACIS® (pronounced a-sis) or automated cellular imaging system is a unique patented technology that detects, counts and classifies cells of clinical interest based on color, size and shape to assist pathologists in making critical medical decisions. Peer-reviewed clinical data and publications have demonstrated that the ACIS digital microscope and proprietary software can considerably improve accuracy and consistency over other methods of laboratory testing. ChromaVision's mission is to improve the quality and reduce the cost of patient care, and speed drug discovery. Many of the top clinical laboratories, hospitals, university medical centers and biopharmaceutical companies in the United States and Europe have adopted the company's technology.